Dr. Schroeder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 314-454-8304Fax+1 314-454-5902
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2006 - 2009- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2003 - 2006
University of Cincinnati College of MedicineClass of 2003
Certifications & Licensure
IL State Medical License 2018 - 2026
MO State Medical License 2006 - 2026- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant Start of enrollment: 2015 Mar 25
- A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2016 Dec 01
Publications & Presentations
PubMed
- Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation.Ramzi Abboud, Mark A Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao
Blood. 2024-11-22 - A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma.Scott R Goldsmith, Michael J Slade, Mark Fiala, Melinda Harding, Zachary D Crees
Annals of Hematology. 2024-11-01 - binds to CELF2 in newly diagnosed multiple myeloma promoting short progression-free survival to standard therapy.Richa Mishra, Prasanth Thunuguntla, Alani Perkin, Dhanusha Duraiyan, Katelyn Bagwill
Research Square. 2024-10-15
Journal Articles
- Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell TransplantationM A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature
Abstracts/Posters
- Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple MyelomaMark A. Schroeder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...Mark A. Schroeder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The Ire of IRE1_: Overexpression of IRE1_ at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1_ Expression Is Predictive of Therapy ...Mark A. Schroeder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
SYNTHETIC BIOLOGICS, INC. MANAGEMENT's DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (Form 10-Q)August 11th, 2022- Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraftOctober 23rd, 2020
- St. Louis: One of the Fastest-Growing Life Sciences MarketsMarch 27th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
